Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencingmarketing2021-02-11T21:47:46+00:00May 19th, 2020|更多详细信息
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatmentmarketing2021-02-15T19:48:14+00:00May 6th, 2020|更多详细信息
Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myelomamarketing2021-02-11T21:50:38+00:00May 1st, 2020|更多详细信息
Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV statusmarketing2021-02-11T21:53:32+00:00April 1st, 2020|更多详细信息
Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complicationsmarketing2021-02-11T21:56:18+00:00March 1st, 2020|更多详细信息
日本MHLW批准Invivoscribe公司的LeukoStrat CDx FLT3突变试剂盒作为第一三共制药公司的Quizartinib的伴随诊断,用于复发/难治性FLT3-ITD AML的治疗。 扩展使用包括收集在EDTA的样本marketing2022-01-03T02:51:50+00:00June 19th, 2019|更多详细信息
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignanciesmarketing2021-02-26T19:10:45+00:00May 21st, 2019|更多详细信息
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in Japanmarketing2021-02-26T19:11:02+00:00November 29th, 2018|更多详细信息
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinibmarketing2021-02-26T19:11:39+00:00November 19th, 2018|更多详细信息